Table 1: Selected hematological parameters in patients with psoriasis as compared to nonpsoriatic controls and their relation to the Psoriasis Area and Severity Index (PASI).

Author, year [ref.]Number of patients/controlsMean/median PASI or BSACorrelation to PASI

C-reactive protein
 Chodorowska et al., 2004 [51]175/3029.2ND
 Coimbra et al., 2010 [52]73/3818.0In correlation with PASI
 Takahashi et al., 2014 [49]97/7910.6/9.2 (male/female)Not associated with PASI
 Vachatova et al., 2016 [44]74/65Median
15.3
ND
Interleukin-6
 Coimbra et al., 2010 [55]66/3718.8In correlation with PASI
 Deeva et al., 2010 [56]35/108.7Not associated with PASI
 Kaur et al., 2012 [57]58/589.5In correlation with PASI
Adiponectin
 Coimbra et al., 2009 [54]56/3719.2ND
 Gerdes et al., 2011 [73]79/8012.2
Not associated with PASI
 Kaur et al., 2011 [50]60/4410.1NS (all patients)ND
 Li et al., 2014 [37]122/134Median BSA 2.9%ND
 Baran et al., 2015 [43]49/1616.5Not associated with PASI
 Vachatova et al., 2016 [44]74/65Median 15.3NSND
LEPTIN
 Gerdes et al., 2011 [73]79/80Median 12.2NSNot associated with PASI
 Kaur et al., 2011 [50]60/4810.1NS (all patients)Not associated with PASI
 Li et al., 2014 [37]122/134Median BSA 2.9%NSND
 Baran et al., 2015 [43]49/1616.5Not associated with PASI
 Vachatova et al., 2016 [44]74/65Median
15.3
ND
 Coimbra et al., 2010 [55]66/3718.8ND

PASI: Psoriasis Area and Severity Index. (the interpretation of PASI score differed between the studies. In most studies, the score below 10 was interpreted as mild disease, between 10 and 20 as moderate, and above 20 as severe disease.) BSA: body surface area; : increased in patients; : decreased in patients; NS: not significant; ND: not done; mild disease.